Lead Sponsor

University of Illinois at Chicago

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•1. Patients meeting criteria for symptomatic myeloma
•2. Patients must be high or intermediate risk of disease progression as defined by having one of the following criteria: 2.1 ISS stage 2 or 3 disease 2.2 Abnormal metaphase cytogenetics 2.3 Presence of FISH abnormalities aside from hyperdiploidy
•3. Patients who have received at least 2 cycles of systemic treatment of any kind in the preceding 12 months
•4. Patient age 18-75 years at time of enrollment
•5. Karnofsky performance status of ≥70
•6. Cardiac function: LVEF \>40%
•7. Hepatic: Bilirubin \<2x upper limit of normal and ALT and AST \< 2.5x the upper limit of normal
•8. Renal: Creatinine clearance of ≥30mL/min, estimated or calculated
•9. Pulmonary: DLCO, FEV1, FVC \>50% of predicted (after correction for hemoglobin)

•1. Patients with diagnosis of plasma cell leukemia
•2. Patients with myeloma who have had any disease progression prior to enrollment
•3. Patients with truly non secretory myeloma (patients with light chain disease are eligible)
•4. Pregnant or breast-feeding
•5. Uncontrolled viral, fungal or bacterial infection Note: Infection is permitted if there is evidence of response to medication. Eligibility of HIV infected patients will be determined on a case-by-case basis.
•6. Patients who have undergone prior allograft or autologous transplant
•7. Prior solid organ transplant
•8. Patients receiving prior radiation to more than 20% of bone marrow containing areas

Related studies

NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma

NCT06215118 · Multiple Myeloma

NCT06679101 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma

NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more

NCT06870760 · Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy, and more

Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma